Central Nervous System Prophylaxis Utilization in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Within...

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• The role of central nervous system (CNS) prophylaxis in diffuse large B-cell lymphoma (DLBCL) remains debated.
• The CNS International Prognostic Index (IPI) aids in identifying high-risk patients for CNS relapse.
• Real-world application of CNS-IPI in guiding prophylaxis decisions is not well-understood.

Purpose of the Study:

• To investigate the utilization of CNS prophylaxis in a DLBCL patient population.
• To assess the documentation and use of the CNS-IPI score in clinical practice.
• To evaluate the impact of CNS prophylaxis on CNS disease progression and survival.

Main Methods:

• Retrospective evaluation of newly diagnosed DLBCL patients (2014-2017).
• Assessment of CNS prophylaxis receipt (intrathecal chemotherapy, high-dose IV methotrexate).
• Calculation of CNS-IPI scores for relevant patient groups; five-year outcome analysis.

Main Results:

• Only 8.6% of 234 patients received CNS prophylaxis (mostly intrathecal methotrexate).
• No CNS disease occurred in the intrathecal group; 2/8 in the IV methotrexate group had CNS involvement.
• CNS progression incidence was 3.7% (no prophylaxis) vs. 10% (prophylaxis).

Conclusions:

• Low utilization of CNS prophylaxis and CNS-IPI documentation was observed in a community hospital system.
• Efficacy claims of CNS prophylaxis cannot be made due to group differences; CNS relapse rates align with literature.
• Continued evaluation of current CNS prophylaxis strategies is warranted, with a need for novel, effective therapies.